{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:10:05Z","timestamp":1778310605079,"version":"3.51.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1996,10]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>Pharmacological stress imaging with adenosine or dipyridamole is associated with a high incidence of side effects, including hypotension, chest pain, AV conduction abnormalities, and bronchospasm. Although the desired coronary vasodilatory response is mediated primarily by the adenosine A<jats:sub>2A<\/jats:sub>receptors, these side effects result from stimulation of the A<jats:sub>1<\/jats:sub>, A<jats:sub>2B<\/jats:sub>, or A<jats:sub>3<\/jats:sub>adenosine receptors. We hypothesized that a selective adenosine A<jats:sub>2A<\/jats:sub>receptor agonist would induce coronary vasodilatation appropriate for pharmacological stress imaging, without evoking adenosine receptor\u2013mediated side effects.<\/jats:p><jats:p><jats:italic>Methods and Results<\/jats:italic>Infusions of a potent and selective A<jats:sub>2A<\/jats:sub>adenosine receptor agonist, WRC-0470 (0.1 to 3 \u03bcg \u00b7 kg<jats:sup>\u22121<\/jats:sup>\u00b7min<jats:sup>\u22121<\/jats:sup>for 10 minutes), to five open-chest dogs produced dose-related left anterior descending (LAD) and left circumflex (LCx) coronary artery vasodilatation without altering mean arterial pressure, heart rate, left atrial pressure, or left ventricular dP\/dt. In the same dogs, adenosine (300 \u03bcg \u00b7 kg<jats:sup>\u22121<\/jats:sup>\u00b7 min<jats:sup>\u22121<\/jats:sup>for 4 minutes) produced coronary vasodilatation that was limited by significant hypotension. To determine the utility of WRC-0470 for pharmacological stress imaging, the hemodynamic responses to WRC-0470 (0.6 \u03bcg \u00b7 kg<jats:sup>\u22121<\/jats:sup>\u00b7 min<jats:sup>\u22121<\/jats:sup>for 10 minutes) and adenosine (250 \u03bcg \u00b7 kg<jats:sup>\u22121<\/jats:sup>\u00b7 min<jats:sup>\u22121<\/jats:sup>for 4 minutes) were compared in dogs with critical LAD stenoses.<jats:sup>201<\/jats:sup>Tl was injected at the peak WRC-0470 stress response. WRC-0470 increased LCx flow nearly fivefold but did not significantly lower mean arterial pressure. Anteroseptal defects were readily apparent in slice images from all dogs. The mean defect ratio (LAD\/LCx) was 0.59\u00b10.06.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>The potent A<jats:sub>2A<\/jats:sub>-selective adenosine receptor agonist WRC-0470 is a short-acting coronary vasodilator with potential utility for pharmacological stress perfusion imaging.<\/jats:p>","DOI":"10.1161\/01.cir.94.7.1726","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:34:42Z","timestamp":1339461282000},"page":"1726-1732","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacological Stress Thallium Scintigraphy With 2-Cyclohexylmethylidenehydrazinoadenosine (WRC-0470)"],"prefix":"10.1161","volume":"94","author":[{"given":"David K.","family":"Glover","sequence":"first","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirta","family":"Ruiz","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Y.","family":"Yang","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Koplan","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry R.","family":"Allen","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Smith","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denny D.","family":"Watson","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Barrett","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Beller","sequence":"additional","affiliation":[{"name":"the Cardiovascular Division, Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, and Discovery Therapeutics, Inc (R.J.B.), Richmond, Va."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_1_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.87.4.8462146"},{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90090-A"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(10)80137-8"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90474-2"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)90424-3"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-3565(25)38124-3","volume":"265","year":"1993","unstructured":"Martin PM, Ueeda M, Olsson RA. 2-Phenylethoxy-9-methyladenine: an adenosine receptor antagonist that discriminates between A2 adenosine receptors in the aorta and the coronary vessels from the guinea pig. J Pharmacol Exp Ther. 1993;265:248-253.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_7_2","first-page":"478A","volume":"23","year":"1994","unstructured":"Nagashima S, Moore HJ, Tracy CM, Solomon AJ, Hewett-Maulman JL, Cowley SM, Woosley RL, Barbey JT. Dose ranging study of N-0861, a new selective A1 adenosine receptor antagonist, in patients receiving adenosine. J Am Coll Cardiol. 1994;23:478A. Abstract.","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_1_8_2","first-page":"278","volume":"31","year":"1994","unstructured":"Hill JA, Bertolet B, Franco E, Kerensky R, Nichols W, Cowley S, Miller J, Belardinelli L. Attenuation of adenosine A1 receptor-mediated effects by N-0861, N6-endonorbornan-2-yl-9-methyladenine, in humans. Drug Dev Res. 1994;31:278. Abstract.","journal-title":"Drug Dev Res"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.88.2.8339412"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00352-Q"},{"key":"e_1_3_1_11_2","first-page":"270","volume":"36","year":"1995","unstructured":"Glover DK, Ruiz M, Sansoy V, Barrett RJ, Beller GA. Effect of N-0861, a selective adenosine A1 receptor antagonist, on pharmacologic stress imaging with adenosine. J Nucl Med. 1995;36:270-275.","journal-title":"J Nucl Med"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00108a014"},{"key":"e_1_3_1_13_2","first-page":"26","volume":"1","year":"1992","unstructured":"Webb RL, Sills MA, Chovan JP, Balwierczak JL, Francis JE. CGS-21680: a potent selective adenosine A2 receptor agonist. Cardiovasc Drug Rev. 1992;1:26-53.","journal-title":"Cardiovasc Drug Rev"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00102a007"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0022-3565(25)20398-6","volume":"259","year":"1991","unstructured":"Webb RL, Barclay BW, Graybill SC. Cardiovascular effects of adenosine A2 agonists in the conscious spontaneously hypertensive rat: a comparative study of three structurally distinct ligands. J Pharmacol Exp Ther. 1991;259:1203-1212.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.91.3.813"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1139\/y92-205"},{"key":"e_1_3_1_18_2","first-page":"55","volume":"20","year":"1987","unstructured":"Heymann MA, Payne BD, Hoffman JIE, Rudolph AM. Blood flow measurement with radionuclide-labeled particles. Prog Cardiovasc Dis. 1987;20:55-79.","journal-title":"Prog Cardiovasc Dis"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)90604-1"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb15902.x"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90365-B"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.81.2.2297867"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(90)90331-I"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(91)90796-C"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(92)90268-Z"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-3581(05)80003-0"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)85277-8"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.94.7.1726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:48:50Z","timestamp":1743364130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.94.7.1726"}},"subtitle":["A Novel, Short-Acting Adenosine A<sub>2A<\/sub>Receptor Agonist"],"short-title":[],"issued":{"date-parts":[[1996,10]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1996,10]]}},"alternative-id":["10.1161\/01.CIR.94.7.1726"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.94.7.1726","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,10]]},"assertion":[{"value":"1995-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-04-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}